$3.95
-0.01 (-0.25%)
Open$4.03
Previous Close$3.96
Day High$4.03
Day Low$3.86
52W High$28.75
52W Low$4.80
Volume—
Avg Volume69.2K
Market Cap9.11M
P/E Ratio—
EPS$-47.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+529.1% upside
Current
$3.95
$3.95
Target
$24.85
$24.85
$15.48
$24.85 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.16M | 3.54M |
| Net Income | -163,651 | -194,157 | -147,578 |
| Profit Margin | -3.9% | -4.7% | -4.2% |
| EBITDA | -229,901 | -240,916 | -206,498 |
| Free Cash Flow | -133,630 | -165,029 | -157,801 |
| Rev Growth | +8.4% | +2.1% | +5.7% |
| Debt/Equity | 0.23 | 0.22 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |